AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00831233
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
Trial: NCT00831233
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
Trial: NCT00135720
Drug: Enbrel (Etanercept)
RxNorm normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06677853
Drug: Timolol Maleate Gel+Placebo
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
Trial: NCT06677853
Drug: Timolol Maleate Gel
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
Trial: NCT04253353
Drug: tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 61 mg capsule
Trial: NCT00648245
Drug: BIO-11006 Inhalation Solution
RxNorm normalized name: Bio-Kool
DrugBank: BIO-11006 (DB14886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of BIO-11006 administered once per day for 21 days by nebulizer
Trial: NCT00648245
Drug: BIO-11006 Inhalation Solution
RxNorm normalized name: Bio-Kool
DrugBank: BIO-11006 (DB14886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of BIO-11006 administered once per day for 21 days by nebulizer
Trial: NCT00648245
Drug: BIO-11006 Inhalation Solution
RxNorm normalized name: Bio-Kool
DrugBank: BIO-11006 (DB14886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
Trial: NCT00648245
Drug: BIO-11006
RxNorm normalized name: BIO-11006
DrugBank: BIO-11006 (DB14886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg BIO-11006 given twice per day for 21 days by nebulizer
Trial: NCT03594825
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Different time of taking medicine
Trial: NCT00042172
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00042172
Drug: Ginkgo Biloba Extract
RxNorm normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00036504
Drug: Insulin Lispro low mixture
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03965728
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
Trial: NCT02265406
Drug: Anti-Infective Agents
RxNorm normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01901848
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
Trial: NCT01901848
Drug: nicotine replacement therapy (NRT)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
Trial: NCT00622115
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04664816
Drug: n-3PUFAs Treatment
RxNorm normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
Trial: NCT00991510
Drug: mycophenolate mofetil (Myfenax)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Trial: NCT00991510
Drug: mycophenolate mofetil (Cellcept)
RxNorm normalized name: MYCOPHENOLATE MOFETIL (CELLCEPT) 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
Trial: NCT00784134
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
Trial: NCT01131299
Drug: Alpha cyclodextrin
RxNorm normalized name: alpha cyclodextrin
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g PO 3 times a day for 12-14 weeks
Trial: NCT04175431
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04175431
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04175431
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00777933
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00777933
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01961752
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Trial: NCT01961752
Drug: Bupivacaine + saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Trial: NCT01961752
Drug: Bupivacaine + triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Trial: NCT04359537
Drug: Hydroxychloroquine Sulfate 200 MG
RxNorm normalized name: hydroxychloroquine sulfate 200 MG
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described
Trial: NCT00643734
Drug: levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg (two 250 mg capsules) by mouth once daily for 7 days
Trial: NCT00251914
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02970552
Drug: Vaginal Progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg micronized vaginal progesterone suppository
Trial: NCT01185028
Drug: Nitazoxanide With Pegylated Interferon And Ribavirin
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
Trial: NCT00407745
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
Trial: NCT02762617
Drug: Tenofovir disoproxil fumarate intravaginal ring
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
Trial: NCT00810862
Drug: pimecrolimus active cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
Trial: NCT02171767
Drug: BIBW 2992 MA2 - single rising dose
RxNorm normalized name: Rise Prot-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01938235
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous bolus and 24-hour infusion of exenatide
Trial: NCT01552369
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
Trial: NCT01885182
Drug: Oxycodone/Naloxone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01885182
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00522990
Drug: AT9283
RxNorm normalized name: AT9283
DrugBank: AT9283 (DB05169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three weekly intravenous administration of AT9283
Trial: NCT00191464
Drug: premeal insulin lispro mixtures
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191464
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191464
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03782480
Drug: Intrarosa
RxNorm normalized name: Intrarosa
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prasterone intravaginal inserts
Trial: NCT01915940
Drug: Bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost ocular insert
Trial: NCT01915940
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol 0.5% solution
Trial: NCT00451152
Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
Trial: NCT03085225
Drug: Combination of trabectedin with durvalumab
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial.
Trial: NCT00097786
Drug: Valsartan 160 mg + nateglinide 60 mg
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Trial: NCT00097786
Drug: Valsartan 160 mg + nateglinide placebo
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Trial: NCT00097786
Drug: Nateglinide 60 mg + valsartan placebo
RxNorm normalized name: nateglinide 60 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Trial: NCT00097786
Drug: Valsartan placebo + nateglinide placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Trial: NCT02607423
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02607423
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02607423
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02607423
Drug: Pemetrexed Disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00891423
Drug: Meropenem short infusion
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00891423
Drug: Meropenem extended infusion
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04632524
Drug: MgSO4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
Trial: NCT03462836
Drug: IV ketamine/lidocaine/IV PCA apply
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
Trial: NCT02443324
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02443324
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT04438850
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
Trial: NCT03836924
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel tablets.
Trial: NCT01502124
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
Trial: NCT01502124
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
Trial: NCT00809237
Drug: Gefitinib, Hydroxychloroquine
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
Trial: NCT00497250
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
Trial: NCT02860819
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib 250mg BID, continuously
Trial: NCT02860819
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 800mg/m2, day 1 and 8
Trial: NCT02860819
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC = 4, day 1
Trial: NCT02999984
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan is used for non-myeloablative conditioning
Trial: NCT02524184
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil 100 mg per day for 7 days.